SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Health, Inc. (NASDAQ:MGLN) today announced financial results for the third quarter ended September 30, 2017, as summarized below:
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||
| September 30 | September 30 | ||||||||||||||||||||
| (In millions, except per share results) | |||||||||||||||||||||
|
2017 |
2016 |
Chg |
2017 |
2016 |
Chg |
||||||||||||||||
| Net revenue | $ | 1,419.4 | $ | 1,292.1 | 9.9% | $ | 4,144.2 | $ | 3,573.5 | 16.0% | |||||||||||
| Net income | $ | 32.5 | $ | 25.5 | 27.5% | $ | 55.7 | $ | 42.7 | 30.4% | |||||||||||
| Segment profit [1] | $ | 87.7 | $ | 82.8 | 5.9% | $ | 211.9 | $ | 199.6 | 6.2% | |||||||||||
| Adjusted net income [1] | $ | 40.4 | $ | 33.3 | 21.3% | $ | 80.6 | $ | 67.1 | 20.1% | |||||||||||
| Per share results: | |||||||||||||||||||||
| Earnings per share | $ | 1.32 | $ | 1.06 | 24.5% | $ | 2.30 | $ | 1.75 | 31.4% | |||||||||||
| Adjusted earnings per share [1] | $ | 1.64 | $ | 1.39 | 18.0% | $ | 3.33 | $ | 2.76 | 20.7% | |||||||||||
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. |
Highlights Include:
- Net revenue increased 10 percent over the third quarter of 2016 to $1.4 billion.
- Net income increased 28 percent over the third quarter of 2016 to $32.5 million.
- Segment profit increased 6 percent over the third quarter of 2016 to $87.7 million.
- Adjusted net income increased 21 percent over the third quarter of 2016 to $40.4 million.
- Unrestricted cash and investments were $480.5 million as of September 30, 2017. Approximately $125.6 million of the unrestricted cash and investments related to excess capital and undistributed earnings held at regulated entities.
- On September 25, 2017, the Company announced that it had completed a $400 million public offering priced at 99.8 percent and bearing interest at 4.40 percent maturing in 2024. In addition, the Company also completed a new $750 million senior unsecured credit agreement.
- Through October 1, 2017, the Company launched in three initial regions in the Commonwealth Coordinated Care Plus Program in Virginia, and will phase-in membership in the remaining regions through January 1, 2018.
- On October 31, 2017, the Company closed on its acquisition of Senior Whole Health.
“I am pleased with the closing of our acquisition of Senior Whole Health, a company focused on serving complex, high-risk populations providing both Medicare and Medicaid dual-eligible benefits in New York and Massachusetts,” said Barry M. Smith chairman and chief executive officer of Magellan Health. “For the balance of the year, we will remain focused on the implementation of our Virginia program and the integration of Senior Whole Health. Success in these major initiatives fuels future growth and fulfills our mission in leading humanity to healthy vibrant lives.”
Net Revenue
Net revenue for the third quarter of 2017 was $1.4 billion, which represents an increase of 10 percent over the same period in 2016. This increase was mainly driven by net business growth and the annualization of revenue from prior year acquisitions.
Segment Profit
Segment profit was $87.7 million for the third quarter of 2017, compared to $82.8 million in the prior year quarter.
- Healthcare segment profit for the third quarter of 2017 was $57.6 million, which represents a decrease of 4 percent compared to the third quarter of 2016. This decrease is mainly due to the prior year quarter including $13 million of favorable out-of-period adjustments, partially off-set by improved results in the government healthcare business.
- Pharmacy segment profit for the third quarter of 2017 was $38.7 million, which was an increase of 20 percent from the third quarter of 2016. The increase was primarily due to PBM new business, improved margins, and earnings from the Veridicus acquisition which closed in December, 2016.
- Corporate costs, inclusive of eliminations but excluding stock compensation expense, were $8.5 million versus $9.4 million during the third quarter of 2016. This decrease was the result of a decline in discretionary benefits.
Cash Flow & Balance Sheet
Cash flow from operations for the nine months ended September 30, 2017 was $112.7 million, as compared to cash flow used by operations of $7.6 million for the nine months ended September 30, 2016. The prior year was impacted by the portion of the contingent consideration payments related to the CDMI acquisition that were recorded in cash flow from operations, and the initial build-up of Medicare Part D receivables.
As of September 30, 2017, the Company’s unrestricted cash and investments totaled $480.5 million versus $293.9 million at December 31, 2016. Approximately $125.6 million of the unrestricted cash and investments at September 30, 2017 related to excess capital and undistributed earnings held at regulated entities.
Restricted cash and investments as of September 30, 2017 increased to $347.7 million versus $315.9 million at December 31, 2016. This variance was primarily due to growth in Magellan Complete Care of Florida and Magellan Complete Care of Virginia.
Outlook
The Company revised its 2017 full year guidance, including the impact of the acquisition of Senior Whole Health which closed on October 31, 2017.
The Company now estimates revenue in the range of $5.75 billion to $5.85 billion. Net Income for the full year 2017 is expected to be in the range of $100 million to $110 million with adjusted net income in the range of $133 million to $143 million. The full year 2017 segment profit guidance is expected to be in the range of $320 million to $330 million.
The Company now estimates cash flow from operations in the range of $210 million to $230 million.
The Company now expects fully diluted EPS to be between $4.10 and $4.51 and fully diluted adjusted EPS to be between $5.45 and $5.86, based on average fully diluted shares of 24.4 million. This updated fully diluted share count reflects share repurchases and option exercises through October 27, but excludes any potential future activity.
“We are updating our full year 2017 guidance to reflect the closing of the Senior Whole Health acquisition, lower segment profit in the Healthcare business and an improved effective tax rate,” said Jonathan N. Rubin, chief financial officer of Magellan Health. “The change in the segment profit outlook reflects an updated view on the timing of corrective actions in commercial healthcare and delays in new business sales.”
| 2017 Guidance | 2017 Guidance | ||||||||||||||||
| Current | Prior [2] | ||||||||||||||||
| (In millions, except per share results) |
Low |
High |
Low |
High |
|||||||||||||
| Net revenue | $ | 5,750.0 | $ | 5,850.0 | $ | 5,795.0 | $ | 6,095.0 | |||||||||
| Net income | $ | 100.0 | $ | 110.0 | $ | 90.0 | $ | 114.0 | |||||||||
| Segment profit [1] | $ | 320.0 | $ | 330.0 | $ | 329.0 | $ | 349.0 | |||||||||
| Adjusted net income [1] | $ | 133.0 | $ | 143.0 | $ | 123.0 | $ | 145.0 | |||||||||
| Cash flow from operations | $ | 210.0 | $ | 230.0 | $ | 150.0 | $ | 182.0 | |||||||||
| Per share results: | |||||||||||||||||
| Earnings per share | $ | 4.10 | $ | 4.51 | $ | 3.72 | $ | 4.71 | |||||||||
| Adjusted earnings per share [1] | $ | 5.45 | $ | 5.86 | $ | 5.08 | $ | 5.99 | |||||||||
| [1] Refer to the Basis of Presentation for a discussion of non-GAAP financial measures. |
| [2] The Company noted in the second quarter earnings release that it expected to be at the lower end of its guidance ranges. |
Earnings Conference Call
Management will discuss the Company’s third quarter results on a conference call scheduled for Wednesday, November 1, 2017 at 10 a.m. Eastern. To participate in the conference call, dial 1-800-857-1812 approximately 10 minutes before the start of the call. The conference call will also be available live via webcast at Magellan's investor relations page at MagellanHealth.com. A telephonic replay will be available shortly after the conclusion of the call through December 1, 2017. This replay may be accessed by dialing 1-800-704-0516 (domestic) or 1-203-369-3323 (international). A replay of the webcast will also be available at the site listed above for 30 days, beginning approximately two hours after its conclusion.
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the Company’s performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, special charges or benefits, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after January 1, 2013 to exclude non-cash stock compensation expense resulting from restricted stock purchases by sellers, changes in the fair value of contingent consideration, amortization of identified acquisition intangibles, as well as impairment of identified acquisition intangibles.
Included in the tables issued with this press release are the reconciliations from GAAP measures to the corresponding non-GAAP measures.
About Magellan Health
Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan supports innovative ways of accessing better health through technology, while remaining focused on the critical personal relationships that are necessary to achieve a healthy, vibrant life. Magellan's customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.
Forward-Looking Statements
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the Securities and Exchange Commission’s Fair Disclosure Regulation. This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties, many of which are out of our control. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding 2017 guidance for net revenue, income before income taxes, net income, earnings per share, segment profit, adjusted net income, adjusted earnings per share, cash flow from operations, growth opportunities and strategy. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the Company’s customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the Company by customers and/or providers; higher utilization of health care services by the Company’s risk members; delays, higher costs or inability to implement new business or other Company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on February 24, 2017, and the Company’s subsequent Quarterly Reports on Form 10-Q filed during 2017. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit, adjusted net income, and adjusted EPS information referred to herein may be considered a non-GAAP financial measure. Further information regarding these measures, including the reasons management considers this information useful to investors, are included in the Company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands) | |||||||
| December 31, 2016 | September 30, 2017 | ||||||
| (unaudited) | |||||||
| ASSETS | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 304,508 | $ | 504,764 | |||
| Accounts receivable, net | 606,764 | 622,431 | |||||
| Short-term investments | 297,493 | 312,902 | |||||
| Pharmaceutical inventory | 58,995 | 48,941 | |||||
| Other current assets | 51,507 | 52,896 | |||||
| Total Current Assets | 1,319,267 | 1,541,934 | |||||
| Property and equipment, net | 172,524 | 161,437 | |||||
| Long-term investments | 7,760 | 10,575 | |||||
| Deferred income taxes | 3,125 | 5,249 | |||||
| Other long-term assets | 12,725 | 40,621 | |||||
| Goodwill | 742,054 | 745,947 | |||||
| Other intangible assets, net | 186,232 | 156,351 | |||||
| Total Assets | $ | 2,443,687 | $ | 2,662,114 | |||
|
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST
AND STOCKHOLDERS' EQUITY |
|||||||
| Current Liabilities: | |||||||
| Accounts payable | $ | 95,635 | $ | 66,530 | |||
| Accrued liabilities | 202,176 | 173,701 | |||||
| Short-term contingent consideration | 9,354 | 8,875 | |||||
| Medical claims payable | 184,136 | 213,692 | |||||
| Other medical liabilities | 197,856 | 193,881 | |||||
| Current debt and capital lease obligations | 403,693 | 19,231 | |||||
| Total Current Liabilities | 1,092,850 | 675,910 | |||||
| Long-term debt and capital lease obligations | 214,686 | 745,543 | |||||
| Tax contingencies | 13,981 | 14,348 | |||||
| Long-term contingent consideration | 1,799 | 615 | |||||
| Deferred credits and other long-term liabilities | 15,882 | 18,290 | |||||
| Total Liabilities | 1,339,198 | 1,454,706 | |||||
| Redeemable non-controlling interest | 4,770 | 4,704 | |||||
| Stockholders’ Equity: | |||||||
| Ordinary common stock | 520 | 527 | |||||
| Additional paid-in capital | 1,186,283 | 1,248,993 | |||||
| Retained earnings | 1,289,288 | 1,344,986 | |||||
| Accumulated other comprehensive loss | (175) | (148) | |||||
| Ordinary common stock in treasury, at cost | (1,376,197) | (1,391,654) | |||||
| Total Stockholders’ Equity | 1,099,719 | 1,202,704 | |||||
| Total Liabilities, Redeemable Non-Controlling Interest and Stockholders’ Equity | $ | 2,443,687 | $ | 2,662,114 | |||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2016 | 2017 | 2016 | 2017 | ||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | ||||||||||||
| Net revenue: | |||||||||||||||
| Managed care and other | $ | 751,589 | $ | 834,358 | $ | 2,127,911 | $ | 2,385,397 | |||||||
| PBM and dispensing | 540,543 | 585,048 | 1,445,588 | 1,758,771 | |||||||||||
| Total net revenue | 1,292,132 | 1,419,406 | 3,573,499 | 4,144,168 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of care | 480,243 | 569,306 | 1,410,403 | 1,634,624 | |||||||||||
| Cost of goods sold | 509,673 | 543,682 | 1,362,062 | 1,648,670 | |||||||||||
| Direct service costs and other operating expenses (1)(2)(3) | 229,094 | 227,372 | 635,627 | 680,230 | |||||||||||
| Depreciation and amortization | 26,885 | 28,189 | 77,472 | 82,896 | |||||||||||
| Interest expense | 3,038 | 7,663 | 6,780 | 16,711 | |||||||||||
| Interest and other income | (741) | (1,781) | (2,116) | (3,801) | |||||||||||
| Total costs and expenses | 1,248,192 | 1,374,431 | 3,490,228 | 4,059,330 | |||||||||||
| Income before income taxes | 43,940 | 44,975 | 83,271 | 84,838 | |||||||||||
| Provision for income taxes | 18,631 | 11,739 | 43,259 | 29,206 | |||||||||||
| Net income | 25,309 | 33,236 | 40,012 | 55,632 | |||||||||||
| Less: net (loss) income attributable to non-controlling interest | (200) | 785 | (2,692) | (66) | |||||||||||
| Net income attributable to Magellan | $ | 25,509 | $ | 32,451 | $ | 42,704 | $ | 55,698 | |||||||
| Weighted average number of common shares outstanding — basic | 23,052 | 23,282 | 23,394 | 23,135 | |||||||||||
| Weighted average number of common shares outstanding — diluted (4) | 24,009 | 24,563 | 24,382 | 24,241 | |||||||||||
| Net income per common share attributable to Magellan — basic | $ | 1.11 | $ | 1.39 | $ | 1.83 | $ | 2.41 | |||||||
| Net income per common share attributable to Magellan — diluted | $ | 1.06 | $ | 1.32 | $ | 1.75 | $ | 2.30 | |||||||
| Net income | $ | 25,309 | $ | 33,236 | $ | 40,012 | $ | 55,632 | |||||||
| Other comprehensive income: | |||||||||||||||
| Unrealized (loss) gains on available-for-sale securities (5) | (127) | 26 | 109 | 27 | |||||||||||
| Comprehensive income | 25,182 | 33,262 | 40,121 | 55,659 | |||||||||||
| Less: comprehensive (loss) income attributable to non-controlling interest | (200) | 785 | (2,692) | (66) | |||||||||||
| Comprehensive income attributable to Magellan | $ | 25,382 | $ | 32,477 | $ | 42,813 | $ | 55,725 | |||||||
| (1) Includes stock compensation expense of $9,176 and $10,323 for the three months ended September 30, 2016 and 2017, respectively, and $27,573 and $31,834 for the nine months ended September 30, 2016 and 2017, respectively. | |
| (2) Includes changes in fair value of contingent consideration of $313 and $(834) for the three months ended September 30, 2016 and 2017, respectively, and $510 and $(631) for the nine months ended September 30, 2016 and 2017, respectively. | |
| (3) Includes impairment of intangible assets of $0 and $4,800 for the three and nine months ended September 30, 2016. | |
| (4) During 2016, the Company early adopted ASU 2016-09. As a result, the common stock equivalents and diluted weighted average common shares outstanding as of September 30, 2016 have been adjusted. There was no impact to net income per common share – diluted. | |
| (5) Net of income tax (benefit) provision of $(78) and $16 for the three months ended September 30, 2016 and 2017, respectively, and $68 and $18 for the nine months ended September 30, 2016 and 2017, respectively. | |
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
| (In thousands) | |||||||
| Nine Months Ended | |||||||
| September 30, | |||||||
| 2016 | 2017 | ||||||
| (Unaudited) | (Unaudited) | ||||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 40,012 | $ | 55,632 | |||
| Adjustments to reconcile net income to net cash from operating activities: | |||||||
| Depreciation and amortization | 77,472 | 82,896 | |||||
| Non-cash impairment of intangible assets | 4,800 | - | |||||
| Non-cash interest expense | 385 | 3,120 | |||||
| Non-cash stock compensation expense | 27,573 | 31,834 | |||||
| Non-cash income tax provision (benefit) | 2,998 | (2,160) | |||||
| Non-cash amortization on investments | 4,224 | 3,052 | |||||
| Changes in assets and liabilities, net of effects from acquisitions of businesses: | |||||||
| Accounts receivable, net | (31,926) | (13,539) | |||||
| Pharmaceutical inventory | (10,425) | 9,609 | |||||
| Other assets | (72,374) | (15,481) | |||||
| Accounts payable and accrued liabilities | 23,870 | (70,006) | |||||
| Medical claims payable and other medical liabilities | (18,017) | 25,578 | |||||
| Contingent consideration | (50,591) | (631) | |||||
| Tax contingencies | (111) | 158 | |||||
| Deferred credits and other long-term liabilities | (5,393) | 2,408 | |||||
| Other | (57) | 210 | |||||
| Net cash (used in) provided by operating activities | (7,560) | 112,680 | |||||
| Cash flows from investing activities: | |||||||
| Capital expenditures | (44,345) | (42,703) | |||||
| Acquisitions and investments in businesses, net of cash acquired | (126,931) | (3,200) | |||||
| Purchase of investments | (365,521) | (341,280) | |||||
| Maturity of investments | 373,694 | 320,045 | |||||
| Net cash used in investing activities | (163,103) | (67,138) | |||||
| Cash flows from financing activities: | |||||||
| Proceeds from issuance of debt | 290,000 | 949,239 | |||||
| Payments to acquire treasury stock | (106,806) | (15,457) | |||||
| Proceeds from exercise of stock options and warrants | 10,933 | 28,328 | |||||
| Payments on debt and capital lease obligations | (13,569) | (798,359) | |||||
| Payments on contingent consideration | (40,559) | (1,032) | |||||
| Other | 1,274 | (8,005) | |||||
| Net cash provided by financing activities | 141,273 | 154,714 | |||||
| Net (decrease) increase in cash and cash equivalents | (29,390) | 200,256 | |||||
| Cash and cash equivalents at beginning of period | 249,029 | 304,508 | |||||
| Cash and cash equivalents at end of period | $ | 219,639 | $ | 504,764 | |||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT | |||||||||||||||
| (In thousands) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2016 | 2017 | 2016 | 2017 | ||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | ||||||||||||
|
Healthcare |
|||||||||||||||
| Managed care and other revenue | $ | 690,572 | $ | 769,451 | $ | 1,947,470 | $ | 2,190,097 | |||||||
| Cost of care | (480,243) | (569,306) | (1,410,403) | (1,634,624) | |||||||||||
| Direct service costs and other | (152,992) | (143,550) | (418,574) | (428,432) | |||||||||||
| Stock compensation expense (1) | 2,267 | 2,623 | 6,737 | 8,388 | |||||||||||
| Changes in fair value of contingent consideration (1) | 313 | (834) | 383 | (631) | |||||||||||
| Impairment of intangible assets (1) | - | - | 4,800 | - | |||||||||||
| Less: non-controlling interest segment profit (loss) (2) | (189) | 789 | (1,325) | (56) | |||||||||||
| Healthcare segment profit | 60,106 | 57,595 | 131,738 | 134,854 | |||||||||||
|
Pharmacy Management |
|||||||||||||||
| Managed care and other revenue | 61,106 | 65,131 | 180,658 | 195,970 | |||||||||||
| PBM and dispensing revenue | 570,231 | 618,178 | 1,535,864 | 1,856,856 | |||||||||||
| Cost of goods sold | (538,113) | (575,327) | (1,448,699) | (1,742,610) | |||||||||||
| Direct service costs and other | (66,475) | (74,976) | (191,402) | (225,782) | |||||||||||
| Stock compensation expense (1) | 5,368 | 5,680 | 16,338 | 17,094 | |||||||||||
| Changes in fair value of contingent consideration (1) | - | - | 127 | - | |||||||||||
| Pharmacy Management segment profit | 32,117 | 38,686 | 92,886 | 101,528 | |||||||||||
|
Corporate and Elimination (3) |
|||||||||||||||
| Managed care and other revenue | (89) | (224) | (217) | (670) | |||||||||||
| PBM and dispensing revenue | (29,688) | (33,130) | (90,276) | (98,085) | |||||||||||
| Cost of goods sold | 28,440 | 31,645 | 86,637 | 93,940 | |||||||||||
| Direct service costs and other | (9,627) | (8,846) | (25,651) | (26,016) | |||||||||||
| Stock compensation expense (1) | 1,541 | 2,020 | 4,498 | 6,352 | |||||||||||
| Less: non-controlling interest segment profit (loss) (2) | (5) | (1) | (16) | (3) | |||||||||||
| Corporate and Elimination | (9,418) | (8,534) | (24,993) | (24,476) | |||||||||||
|
Consolidated |
|||||||||||||||
| Managed care and other revenue | 751,589 | 834,358 | 2,127,911 | 2,385,397 | |||||||||||
| PBM and dispensing revenue | 540,543 | 585,048 | 1,445,588 | 1,758,771 | |||||||||||
| Cost of care | (480,243) | (569,306) | (1,410,403) | (1,634,624) | |||||||||||
| Cost of goods sold | (509,673) | (543,682) | (1,362,062) | (1,648,670) | |||||||||||
| Direct service costs and other | (229,094) | (227,372) | (635,627) | (680,230) | |||||||||||
| Stock compensation expense (1) | 9,176 | 10,323 | 27,573 | 31,834 | |||||||||||
| Changes in fair value of contingent consideration (1) | 313 | (834) | 510 | (631) | |||||||||||
| Impairment of intangible assets (1) | - | - | 4,800 | - | |||||||||||
| Less: non-controlling interest segment profit (loss) (2) | (194) | 788 | (1,341) | (59) | |||||||||||
| Consolidated segment profit | $ | 82,805 | $ | 87,747 | $ | 199,631 | $ | 211,906 | |||||||
| Reconciliation of income before income taxes to segment profit: | |||||||||||||||
| Income before income taxes | $ | 43,940 | $ | 44,975 | $ | 83,271 | $ | 84,838 | |||||||
| Stock compensation expense | 9,176 | 10,323 | 27,573 | 31,834 | |||||||||||
| Changes in fair value of contingent consideration | 313 | (834) | 510 | (631) | |||||||||||
| Impairment of intangible assets | - | - | 4,800 | - | |||||||||||
| Non-controlling interest segment (profit) loss | 194 | (788) | 1,341 | 59 | |||||||||||
| Depreciation and amortization | 26,885 | 28,189 | 77,472 | 82,896 | |||||||||||
| Interest expense | 3,038 | 7,663 | 6,780 | 16,711 | |||||||||||
| Interest and other income | (741) | (1,781) | (2,116) | (3,801) | |||||||||||
| Segment profit | $ | 82,805 | $ | 87,747 | $ | 199,631 | $ | 211,906 | |||||||
| (1) Stock compensation expense, changes in the fair value of contingent consideration recorded in relation to acquisitions and impairment of intangible assets are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit. | |
| (2) The non-controlling portion of AlphaCare's segment profit (loss) is excluded from the computation of segment profit. | |
| (3) Healthcare subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Healthcare’s customers. In addition, Pharmacy Management provides pharmacy benefits management for the Company’s employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated. | |
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||
| NON-GAAP MEASURES | |||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2016 | 2017 | 2016 | 2017 | ||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | ||||||||||||
| Net income attributable to Magellan | $ | 25,509 | $ | 32,451 | $ | 42,704 | $ | 55,698 | |||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||
| Stock compensation expense relating to acquisitions | 5,105 | 4,960 | 14,217 | 14,718 | |||||||||||
| Changes in fair value of contingent consideration | 313 | (834) | 510 | (631) | |||||||||||
| Amortization of acquired intangibles | 6,649 | 8,424 | 17,938 | 25,189 | |||||||||||
| Impairment of intangible assets, net of non-controlling interest | - | - | 3,936 | - | |||||||||||
| Tax impact | (4,254) | (4,605) | (12,203) | (14,372) | |||||||||||
| Adjusted net income | $ | 33,322 | $ | 40,396 | $ | 67,102 | $ | 80,602 | |||||||
| Net income per common share attributable to Magellan —Diluted |
$ |
1.06 | $ | 1.32 | $ | 1.75 | $ | 2.30 | |||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||
| Stock compensation expense relating to acquisitions | 0.22 | 0.20 | 0.59 | 0.61 | |||||||||||
| Changes in fair value of contingent consideration | 0.01 | (0.03) | 0.02 | (0.03) | |||||||||||
| Amortization of acquired intangibles | 0.28 | 0.34 | 0.74 | 1.04 | |||||||||||
| Impairment of intangible assets, net of non-controlling interest | - | - | 0.16 | - | |||||||||||
| Tax impact | (0.18) | (0.19) | (0.50) | (0.59) | |||||||||||
| Adjusted earnings per share | $ | 1.39 | $ | 1.64 | $ | 2.76 | $ | 3.33 | |||||||
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||
| FISCAL 2017 GUIDANCE | |||||||||||||||
| (In millions, except per share amounts) | |||||||||||||||
| PREVIOUS GUIDANCE | CURRENT GUIDANCE (1) | ||||||||||||||
| Low | High | Low | High | ||||||||||||
| Net revenue | $ | 5,795.0 | $ | 6,095.0 | $ | 5,750.0 | $ | 5,850.0 | |||||||
| Income before income taxes | 149.0 | 189.0 | 143.0 | 157.0 | |||||||||||
| Net income | 90.0 | 114.0 | 100.0 | 110.0 | |||||||||||
| Segment profit (2) | 329.0 | 349.0 | 320.0 | 330.0 | |||||||||||
| Adjusted net income (2) | 123.0 | 145.0 | 133.0 | 143.0 | |||||||||||
| Cash flow from operations | 150.0 | 182.0 | 210.0 | 230.0 | |||||||||||
| Per share results: | |||||||||||||||
| Earnings per share (3) | 3.72 | 4.71 | 4.10 | 4.51 | |||||||||||
| Adjusted earnings per share (2)(3) | 5.08 | 5.99 | 5.45 | 5.86 | |||||||||||
| (1) Includes two months of Senior Whole Health's results. |
| (2) Refer to the Reconciliation of GAAP to Non-GAAP measures table. |
| (3) Based on average fully diluted shares of 24.2 million and 24.4 million for previous guidance and current guidance, respectively. |
| MAGELLAN HEALTH, INC. AND SUBSIDIARIES | |||||||||||||||||||
| FISCAL 2017 GUIDANCE | |||||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP MEASURES | |||||||||||||||||||
| (In millions, except per share amounts) | |||||||||||||||||||
| PREVIOUS GUIDANCE |
CURRENT GUIDANCE (1) |
||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||
| Net income attributable to Magellan | $ | 90.0 | $ | 114.0 | $ | 100.0 | $ | 110.0 | |||||||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||||||
| Stock compensation expense relating to acquisitions | 16.7 | 16.7 | 16.5 | 16.5 | |||||||||||||||
| Changes in fair value of contingent consideration | 2.0 | - | - | - | |||||||||||||||
| Amortization of acquired intangibles | 34.0 | 34.0 | 35.5 | 35.5 | |||||||||||||||
| Tax impact | (19.7 | ) | (19.7 | ) | (19.0 | ) | (19.0 | ) | |||||||||||
| Adjusted net income | $ | 123.0 | $ | 145.0 | $ | 133.0 | $ | 143.0 | |||||||||||
| Net income per common share attributable to Magellan —Diluted | $ | 3.72 | $ | 4.71 | $ | 4.10 | $ | 4.51 | |||||||||||
| Adjusted for acquisitions starting in 2013 | |||||||||||||||||||
| Stock compensation expense relating to acquisitions | 0.69 | 0.69 | 0.68 | 0.68 | |||||||||||||||
| Changes in fair value of contingent consideration | 0.08 | - | - | - | |||||||||||||||
| Amortization of acquired intangibles | 1.40 | 1.40 | 1.45 | 1.45 | |||||||||||||||
| Tax impact | (0.81 | ) | (0.81 | ) | (0.78 | ) | (0.78 | ) | |||||||||||
| Adjusted earnings per share | $ | 5.08 | $ | 5.99 | $ | 5.45 | $ | 5.86 | |||||||||||
| Reconciliation of income before income taxes to segment profit: | |||||||||||||||||||
| Income before income taxes | $ | 149.0 | $ | 189.0 | $ | 143.0 | $ | 157.0 | |||||||||||
| Stock compensation expense | 40.0 | 36.0 | 41.0 | 39.0 | |||||||||||||||
| Changes in fair value of contingent consideration | 2.0 | - | - | - | |||||||||||||||
| Depreciation and amortization | 117.0 | 113.0 | 115.0 | 113.0 | |||||||||||||||
| Interest expense | 23.0 | 13.0 | 26.0 | 26.0 | |||||||||||||||
| Interest income | (2.0 | ) | (2.0 | ) | (5.0 | ) | (5.0 | ) | |||||||||||
| Segment profit | $ | 329.0 | $ | 349.0 | $ | 320.0 | $ | 330.0 | |||||||||||
| (1) Includes two months of Senior Whole Health's results. |
